Phaseline

Companies › Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Anti-FLT3 CAR-T cells
Anti-FLT3 chimeric antigen receptor T-cell therapy
FLT3Phase 1Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)Jan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06786533Anti-FLT3 CAR-T cellsPhase 1Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)OncologyJan 2027

Targets

FLT3 (1)

Companies with the same targets

Daiichi Sankyo Sunshine Lake Pharma Ryvu Therapeutics Bristol-Myers Squibb Novartis Cullinan Therapeutics Aptose Biosciences Etnova Therapeutics Swedish Orphan Biovitrum Theradex

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.